MedTrace Logo

Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis

NCT01214187 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2017-06-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether low concentration inhaled carbon monoxide is effective in treating idiopathic pulmonary fibrosis.

Conditions

Interventions

DRUG

inhaled carbon monoxide

The intervention will be inhaled CO at 100-200 ppm administered two times weekly for two hours per dose to complete 12 weeks of treatment.

OTHER

Oxygen

Room air oxygen concentrations will be administered as placebo

Sponsors & Collaborators

Principal Investigators

  • Rosas O Ivan, MD · Brigham and Women's Hospital

  • Joe GN Garcia, MD · University of Illinois at Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2014-10-31
Completion
2015-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01214187 on ClinicalTrials.gov